VEGFA and neoplasm: Although initial evidence suggested that a rapid increase in the serum VEGF-A concentration may be a potential predictor of resistance to bevacizumab, Alidzanovic et al. [111] demonstrated that the increase of VEGF circulating levels, during bevacizumab-based treatment, should not be considered as a tumor escape mechanism, but rather a pharmacodynamic effect: the measured VEGF is largely complicated by bevacizumab [110].